Summary
This umbrella review synthesised 12 systematic reviews (2016–June 2026) on omega-3 and PUFA interventions for dry eye disease, finding reported benefits most frequent for symptoms and tear break-up time but inconsistent objective signs. Only two reviews were rated high confidence by AMSTAR 2, with very high overlap (CCA 19.1%) among 50 unique primary studies. The authors conclude that evidence does not support routine omega-3/PUFA treatment across dry eye disease phenotypes, recommending instead more rigorous phenotype-specific trials with standardised interventions and patient-centred outcomes.
Regional applicability
The review synthesised international evidence on PUFA supplementation for dry eye disease and does not report country-specific data. Findings are relevant to United Kingdom clinical practice, where omega-3 supplementation is sometimes offered for dry eye; however, applicability depends on how UK guidelines classify dry eye phenotypes and the similarity of UK trial populations and clinical contexts to those reviewed.
Key measures
Clinical efficacy outcomes (symptoms, tear break-up time, objective signs); AMSTAR 2 confidence ratings; corrected covered area (CCA) for primary-study overlap; heterogeneity estimates across pooled analyses
Outcomes reported
The review synthesised evidence on clinical effects of omega-3 and PUFA interventions for dry eye disease, appraising methodological confidence using AMSTAR 2 and measuring primary-study overlap using corrected covered area. It assessed reported benefits for symptoms, tear break-up time and objective signs across 12 included systematic reviews.
Topic tags
Dig deeper with Pulse AI.
Ask about this record, its theme or its relevance to UK farming and policy. Pulse AI uses selected catalogue evidence and cites the sources it draws on.